Only a handful of people have been treated with Kite Pharmaceuticals' Yescarta since its approval, Bloomberg reports. The CAR T-cell therapy received approval from the US Food and Drug Administration to treat large B-cell lymphoma in October.
To read the full story....
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.